Salud por Derecho, together with four other organisations, has submitted third-party observations to the European Patent Office, calling for a patent application filed by Merck Sharp & Dohme (MSD) rel...

Desde Salud por Derecho hemos presentado, junto a otras cuatro organizaciones, observaciones ante la Oficina Europea de Patentes para pedir que no se conceda una nueva patente solicitada por Merck

Organisations have jointly filed a third-party observation with the European Patent Office (EPO) opposing a patent application filed by Merck Sharp & Dohme LLC (“Merck”) that claims prodrug forms of a...

In adults with low likelihood of human immunodeficiency virus-1 exposure, 6 oral doses of once-monthly alimatravir (3, 6, or 12 mg) demonstrated safety and

Long-acting oral options for human immunodeficiency virus-1 (HIV-1) pre-exposure prophylaxis are needed to address challenges with adherence to once-daily regimens. Alimatravir is an oral nucleoside reverse transcriptase translocation inhibitor with pharmacokinetic properties supporting once-monthly dosing.MethodsIn this double-blind, placebo-controlled study, adults aged 18–65 years with low likelihood of HIV-1 exposure were randomly assigned 2:2:2:1 to receive 6 oral doses of alimatravir (3, 6, or 12 mg) or placebo once every 4 weeks. The primary outcome was the proportion of participants with adverse events through 8 weeks after the last dose, assessed in participants who received at least one dose of study intervention. Additional outcomes were the pharmacokinetics of alimatravir in plasma (all participants) and alimatravir-triphosphate in peripheral blood mononuclear cells (∼ 20 participants from each alimatravir dose group).ResultsThree hundred fifty participants were included in the analyses (median age 28 years; 58% female): 301 received alimatravir 3 mg (n = 101), 6 mg (n = 101), or 12 mg (n = 99) and 49 received placebo. Adverse event rates were comparable for alimatravir 3 mg (61.4% [62/101]), 6 mg (68.3% [69/101]), 12 mg (66.7% [66/99]), and placebo (63.3% [31/49]). Study intervention was discontinued because of an adverse event in 1.0% (3/301) of participants who received alimatravir and 4.1% (2/49) who received placebo. Pharmacokinetic parameters for alimatravir and alimatravir-triphosphate were dose-proportional and support a once-monthly dosing interval.ConclusionsThe favorable safety, tolerability, and pharmacokinetics of alimatravir and alimatravir-triphosphate support continued development of alimatravir as oral monthly pre-exposure prophylaxis.Clinical Trials RegistrationClinicalTrials.gov Identifier NCT06045507; https://www.clinicaltrials.gov/search.

Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill....

The drugmaker cites a lack of government purchase commitments as it focuses on Merck’s experimental monthly pill alimatravir instead

In the latest issue of #PxWire, AVAC’s Mitchell Warren reflects on some of the most important developments coming out of #AIDS2026 and the tension between a pipeline that continues to advance and a gl...

In July 2026, Merck announced licensing agreements with seven manufacturers for generic production of its HIV drug alimatravir, though access and equity concerns remain. Ed Holt reports.

South Africa returned from the International Aids Conference in Rio with three big HIV announcements: a new dashboard tracking the roll-out of the country's six-monthly HIV prevention injection,…

South Africa returned from the International Aids Conference in Rio with three big HIV announcements: a new dashboard tracking the roll-out of the country's six-monthly HIV prevention injection,…

Merck's investigational once-monthly PrEP pill could be manufactured and sold profitably for around $3 per person per year, making it the cheapest HIV prevention drug ever brought to market, the 26th ...

Um novo medicamento contra o vírus HIV será produzido no Brasil pela Fundação Oswaldo Cruz (Fiocruz). A determinação foi confirmada após ser assinado, nesta terça-feira (28), um acordo entre a fundação e a farmacêutica privada MSD, durante a 26ª Conferência Internacional da Aids, no Rio de Janeiro. O antirretroviral se trata do Alimatravir (MK-8527), que […]

Merck's investigational once-monthly PrEP pill could be manufactured and sold profitably for around $3 per person per year, making it the cheapest HIV prevention drug ever brought to market, the 26th ...